This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1: DM Eisenberg , RB David , SL Ettner , Trends in alternative medicine use in the United States, 1990–1997. JAMA 1998; 280: 1569–75.
3: CJ De Weerdt , HPR Bootsma , Hendriks. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1998; 3: 225–30.
4: AR Jadad , RA Moore , D Carrol , C Jenkinson , DJM Reynolds , Gavaghan, Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin. Trials 1996; 17: 1–12.
5: ES Johnson , NP Kadam , DM Hylands , PJ Hylands . Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1998; 291: 569–73.
7: D Palevitch , G Earon , Carasso. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: A double-blind placebo-controlled study. Phytother. Res. 1998; 11: 508–11.
16: P Tfelt-Hansen , SL Nielsen . Patient numbers needed in prophylactic migraine trials. Neuroepidemiology 1997; 6: 214–19.
17: S Heptinstall , WA Groenewegen , P Spangenberg , W. Loesche Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J. Pharm. Pharmacol. 1987; 39: 459–65.
18: WJ Pugh , K. Sambo Prostaglandin synthetase inhibitors in feverfew. J. Pharm. Pharmacol. 1988; 40: 743–5.
20: DVC Awang . Prescribing therapeutic feverfew (Tanacetum parthenium (L.) Schultz Bip., syn. Chrysanthemum parthenium (L.) Bernh.). Integrative Med. 1998; 1: 11–13.
21: PJ Goadsby . How do the currently used prophylactic agents work in migraine?. Cephalalgia 1997; 17: 85–92.
22: AMG Brown , CM Edwards , MR Davey , B Power , KC Lowe . Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): Assessment by inhibition of human polymorphonuclear leucocyte chemiluminescence in-vitro. J. Pharm. Pharmacol. 1998; 49: 558–61.
23: H Hendriks , R Bos , HJ Woerdenbag . The essential oil of Tanacetum parthenium (L.) Schultz-Bip. Flavour Fragrance J. 1996; 11: 367–71.
24: SJ Murch , CB Simmons , PK Saxena . Melatonin in feverfew and other medicinal plants. Lancet 1997; 350: 1598–9.
25: J Brun , B Claustrat , P Saddier , G. Chazor Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995; 15: 136–9.
27: D Anderson , PC Jenkinson , RS Dewdney , SD Blowers , ES Johnson , NP Kadam . Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users. Hum. Toxicol. 1988; 7: 145–52.
28: JN Burry . Compositae dermatitis in South Australia: Contact dermatitis from Chrysanthemum parthenium. Contact Dermatitis 1980; 6: 445.
31: PJ Easterbrook , JA Berlin , R Gopalan , DR Matthews . Publication bias in clinical research. Lancet 1991; 337: 867–72.
32: E Ernst , MH Pittler . Alternative therapy bias [letter]. Nature 1997; 385: 480.
33: MH Pittler , NC Abbot , EF Harkness , E. Ernst Location bias in controlled clinical trials of complementary medicine. J. Clin. Epidemiol. 2000; 53: 485–9.